AC Immune SA (ACIU) Given Consensus Rating of “Buy” by Analysts

AC Immune SA (NASDAQ:ACIU) has received an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $15.25.

Several equities analysts have weighed in on the company. Zacks Investment Research upgraded AC Immune from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Wednesday, November 21st. BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Leerink Swann assumed coverage on AC Immune in a report on Monday, November 12th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, ValuEngine lowered AC Immune from a “buy” rating to a “hold” rating in a report on Monday, August 20th.

NASDAQ ACIU opened at $11.15 on Friday. AC Immune has a fifty-two week low of $7.16 and a fifty-two week high of $17.40. The stock has a market cap of $718.56 million, a price-to-earnings ratio of -37.17 and a beta of 1.27.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Tuesday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. AC Immune had a negative return on equity of 24.14% and a negative net margin of 146.09%. The company had revenue of $2.34 million for the quarter, compared to analyst estimates of $1.71 million. On average, equities research analysts anticipate that AC Immune will post -0.85 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new position in shares of AC Immune in the third quarter worth about $107,000. GSA Capital Partners LLP bought a new position in shares of AC Immune in the third quarter worth about $110,000. JPMorgan Chase & Co. bought a new position in shares of AC Immune in the third quarter worth about $142,000. Compagnie Lombard Odier SCmA increased its stake in shares of AC Immune by 858.3% in the third quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after purchasing an additional 30,039 shares during the period. Finally, Belpointe Asset Management LLC bought a new position in shares of AC Immune in the third quarter worth about $400,000. Institutional investors and hedge funds own 29.06% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: Why investors pay attention to retained earnings

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply